| scholarly article | Q13442814 |
| P2093 | author name string | H L Ford | |
| A Thorburn | |||
| C K Anderson | |||
| R Camidge | |||
| K Behbakht | |||
| L Y Dimberg | |||
| P2860 | cites work | Identification and characterization of a new member of the TNF family that induces apoptosis | Q24318423 |
| Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family | Q24320301 | ||
| Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIX1: a possible mechanism of breast carcinogenesis | Q24644884 | ||
| Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis | Q28584976 | ||
| Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. | Q30999109 | ||
| Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. | Q32046963 | ||
| Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study | Q33385642 | ||
| Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. | Q33385878 | ||
| Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer | Q33397708 | ||
| Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma. | Q33544118 | ||
| Apoptosis control by death and decoy receptors | Q33597389 | ||
| Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors | Q33618126 | ||
| TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitro | Q33802751 | ||
| Safety and antitumor activity of recombinant soluble Apo2 ligand | Q33855449 | ||
| Inducible dimerization and inducible cleavage reveal a requirement for both processes in caspase-8 activation | Q33883310 | ||
| Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. | Q34006269 | ||
| Model-based dissection of CD95 signaling dynamics reveals both a pro- and antiapoptotic role of c-FLIPL. | Q34069986 | ||
| MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers. | Q34124451 | ||
| Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. | Q34561798 | ||
| Enhanced anticancer effect of the combination of cisplatin and TRAIL in triple-negative breast tumor cells | Q34647893 | ||
| Database of p53 gene somatic mutations in human tumors and cell lines | Q34868968 | ||
| Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment | Q34970050 | ||
| Cell surface Death Receptor signaling in normal and cancer cells | Q35091128 | ||
| Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy | Q36112074 | ||
| cFLIP regulation of lymphocyte activation and development | Q36405075 | ||
| TRAIL signalling: decisions between life and death. | Q36778214 | ||
| Who should be sent for genetic testing in hereditary colorectal cancer syndromes? | Q36905417 | ||
| Zinc chelation induces rapid depletion of the X-linked inhibitor of apoptosis and sensitizes prostate cancer cells to TRAIL-mediated apoptosis | Q36979121 | ||
| FLIP as an anti-cancer therapeutic target | Q37096732 | ||
| Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. | Q37231517 | ||
| EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins | Q37262805 | ||
| Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition | Q37328450 | ||
| The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling | Q37328463 | ||
| Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. | Q37515926 | ||
| BH3-only proteins: the death-puppeteer's wires | Q37629756 | ||
| Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer | Q37644600 | ||
| TRAILing death in cancer | Q37648864 | ||
| Death receptor agonists as a targeted therapy for cancer | Q37701624 | ||
| TRAIL receptor signaling and therapeutics. | Q37785559 | ||
| An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis | Q38290395 | ||
| c-FLIPR, a new regulator of death receptor-induced apoptosis. | Q38330819 | ||
| Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab | Q38417726 | ||
| Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. | Q38433102 | ||
| Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents. | Q39583729 | ||
| In vitro and in vivo characterisation of a novel c-FLIP-targeted antisense phosphorothioate oligonucleotide | Q39671672 | ||
| Preclinical and clinical estimates of the basal apoptotic rate of a cancer predict the amount of apoptosis induced by subsequent proapoptotic stimuli | Q39680243 | ||
| FLIP(L) induces caspase 8 activity in the absence of interdomain caspase 8 cleavage and alters substrate specificity | Q39694237 | ||
| ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis | Q39965483 | ||
| TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. | Q40070558 | ||
| Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding | Q40100090 | ||
| Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer | Q40126331 | ||
| Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. | Q40149403 | ||
| Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein | Q40163044 | ||
| Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. | Q40287620 | ||
| Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells | Q40333025 | ||
| Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer | Q40359028 | ||
| Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor | Q40363687 | ||
| Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer | Q40405998 | ||
| Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. | Q40553526 | ||
| Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. | Q40554408 | ||
| X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells | Q40559201 | ||
| X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mito | Q40683606 | ||
| TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy | Q40776719 | ||
| Molecular determinants of response to TRAIL in killing of normal and cancer cells. | Q40898104 | ||
| Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. | Q40975748 | ||
| Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. | Q41747264 | ||
| The c-FLIP-NH2 terminus (p22-FLIP) induces NF-kappaB activation. | Q42772785 | ||
| Increased expression of Mcl-1 is responsible for the blockage of TRAIL-induced apoptosis mediated by EGF/ErbB1 signaling pathway | Q42798518 | ||
| Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation | Q42814954 | ||
| Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice | Q43860748 | ||
| Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. | Q43903493 | ||
| Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice | Q44124109 | ||
| TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. | Q44482351 | ||
| Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells | Q45205072 | ||
| LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors | Q45866584 | ||
| TRAIL-R as a negative regulator of innate immune cell responses. | Q45954066 | ||
| Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. | Q46061571 | ||
| Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation | Q46267730 | ||
| Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. | Q46463388 | ||
| Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae | Q46853181 | ||
| Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes | Q47393603 | ||
| Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release | Q47999102 | ||
| A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. | Q51700126 | ||
| Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. | Q52834067 | ||
| Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. | Q53527119 | ||
| Reduced apoptosis and ameliorated listeriosis in TRAIL-null mice. | Q53882254 | ||
| Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. | Q55473556 | ||
| Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer | Q60620763 | ||
| Cutting Edge: TRAIL Deficiency Accelerates Hematological Malignancies | Q62623641 | ||
| Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages | Q73590308 | ||
| Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions | Q73704158 | ||
| Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand | Q73766150 | ||
| TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma | Q83919556 | ||
| Overcoming TRAIL resistance in ovarian carcinoma | Q84575154 | ||
| A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors | Q85196462 | ||
| Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors | Q94703959 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1341-1350 | |
| P577 | publication date | 2012-05-14 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics | |
| P478 | volume | 32 |
| Q38858308 | 5-Fluorouracil preferentially sensitizes mutant KRAS non-small cell lung carcinoma cells to TRAIL-induced apoptosis |
| Q51176917 | A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance. |
| Q36170989 | A Microplate-Based Nonradioactive Protein Synthesis Assay: Application to TRAIL Sensitization by Protein Synthesis Inhibitors |
| Q39811568 | A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers |
| Q38882537 | A fate worse than death: apoptosis as an oncogenic process |
| Q36332681 | A promising "TRAIL" of tanshinones for cancer therapy |
| Q30361915 | A set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in lung cancer. |
| Q36216032 | ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer |
| Q39247899 | Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile |
| Q39118820 | Additive effect of sirolimus and anti-death receptor 5 agonistic antibody against hepatocellular carcinoma |
| Q34260349 | Aplysin sensitizes cancer cells to TRAIL by suppressing P38 MAPK/survivin pathway |
| Q39643632 | Association between breast cancer and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) gene 1595C/T SNP in a Pakistani population. |
| Q33584607 | Autophagy and cancer therapy |
| Q90687227 | Autophagy as a mechanism of Apo2L/TRAIL resistance |
| Q60958902 | Autophagy flux inhibition mediated by celastrol sensitized lung cancer cells to TRAIL‑induced apoptosis via regulation of mitochondrial transmembrane potential and reactive oxygen species |
| Q64071055 | Autophagy inhibitors regulate TRAIL sensitivity in human malignant cells by targeting the mitochondrial network and calcium dynamics |
| Q38721364 | Bayesian Network Inference Modeling Identifies TRIB1 as a Novel Regulator of Cell-Cycle Progression and Survival in Cancer Cells |
| Q52373692 | CASC2/miR-24/miR-221 modulates the TRAIL resistance of hepatocellular carcinoma cell through caspase-8/caspase-3. |
| Q39063100 | CD40-directed scFv-TRAIL fusion proteins induce CD40-restricted tumor cell death and activate dendritic cells |
| Q39028796 | CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants |
| Q52583854 | Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells. |
| Q30398758 | Caspase-8 activation by TRAIL monotherapy predicts responses to IAPi and TRAIL combination treatment in breast cancer cell lines |
| Q26996626 | Caspase-8 as a regulator of tumor cell motility |
| Q42292360 | Caspases play in traffic |
| Q38169790 | Chimeric rodents with humanized liver: bridging the preclinical/clinical trial gap in ADME/toxicity studies |
| Q54241755 | Circulating Levels of Inflammatory Proteins and Survival in Patients with Gallbladder Cancer. |
| Q55413541 | Cold PSM, but not TRAIL, triggers autophagic cell death: A therapeutic advantage of PSM over TRAIL. |
| Q64284731 | Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells |
| Q39126075 | Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling |
| Q38244150 | Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2. |
| Q38180799 | Cytokine networking of innate immunity cells: a potential target of therapy. |
| Q42123656 | Death Receptor 5 Networks Require Membrane Cholesterol for Proper Structure and Function. |
| Q47108799 | Death Receptors: New Opportunities in Cancer Therapy |
| Q36395984 | Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors |
| Q26853365 | Depolarization Controls TRAIL-Sensitization and Tumor-Selective Killing of Cancer Cells: Crosstalk with ROS |
| Q57279753 | Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL |
| Q37269205 | Discovery and characterization of Isofistularin-3, a marine brominated alkaloid, as a new DNA demethylating agent inducing cell cycle arrest and sensitization to TRAIL in cancer cells |
| Q38865798 | Distinct effects of TRAIL on the mitochondrial network in human cancer cells and normal cells: role of plasma membrane depolarization |
| Q91812392 | Double-Edged Lipid Nanoparticles Combining Liposome-Bound TRAIL and Encapsulated Doxorubicin Showing an Extraordinary Synergistic Pro-Apoptotic Potential |
| Q38823727 | Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death. |
| Q34149887 | EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells |
| Q35600313 | Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine |
| Q38918317 | Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells |
| Q34980866 | Evidence for two modes of synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia in human colon cancer cells |
| Q34929094 | Expression of TRAIL-splice variants in gastric carcinomas: identification of TRAIL-γ as a prognostic marker |
| Q53075808 | Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation. |
| Q37362742 | Extracellular miR-1246 promotes lung cancer cell proliferation and enhances radioresistance by directly targeting DR5. |
| Q35705510 | Fractional killing arises from cell-to-cell variability in overcoming a caspase activity threshold |
| Q41192295 | Functional Detection of TNF Receptor Family Members by Affinity-Labeled Ligands |
| Q39205404 | Functional roles of tumor necrosis factor-related apoptosis-inducing ligand-DR5 interaction in B16F10 cells by activating the nuclear factor-κB pathway to induce metastatic potential |
| Q38131166 | Genetics and biomarkers in personalisation of lung cancer treatment |
| Q37739975 | Gold nanoparticles enhance TRAIL sensitivity through Drp1-mediated apoptotic and autophagic mitochondrial fission in NSCLC cells |
| Q53688757 | Herbal Medicines Showing Synergistic Effects with Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) against A549 TRAIL-resistant Lung Cancer Cells: A Screening Study. |
| Q64056288 | Hsp90 Inhibitor SNX-2112 Enhances TRAIL-Induced Apoptosis of Human Cervical Cancer Cells via the ROS-Mediated JNK-p53-Autophagy-DR5 Pathway |
| Q35982020 | HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells |
| Q42915261 | Human embryonic and induced pluripotent stem cells express TRAIL receptors and can be sensitized to TRAIL-induced apoptosis. |
| Q42577813 | Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme |
| Q92756792 | Importance of TRAIL Molecular Anatomy in Receptor Oligomerization and Signaling. Implications for Cancer Therapy |
| Q39064919 | Indomethacin sensitizes TRAIL-resistant melanoma cells to TRAIL-induced apoptosis through ROS-mediated upregulation of death receptor 5 and downregulation of survivin. |
| Q47148273 | Inorganic Kernel-Reconstituted Lipoprotein Biomimetic Nanovehicles Enable Efficient Targeting "Trojan Horse" Delivery of STAT3-Decoy Oligonucleotide for Overcoming TRAIL Resistance |
| Q28115758 | Integrative analysis of kinase networks in TRAIL-induced apoptosis provides a source of potential targets for combination therapy |
| Q52721892 | Involvement of AMP-activated protein kinase and Death Receptor 5 in TRAIL-Berberine-induced apoptosis of cancer cells. |
| Q41228765 | JWA regulates TRAIL-induced apoptosis via MARCH8-mediated DR4 ubiquitination in cisplatin-resistant gastric cancer cells |
| Q41084396 | KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL. |
| Q38927052 | Kurarinone Synergizes TRAIL-Induced Apoptosis in Gastric Cancer Cells |
| Q55022368 | Lambertianic Acid Sensitizes Non-Small Cell Lung Cancers to TRAIL-Induced Apoptosis via Inhibition of XIAP/NF-κB and Activation of Caspases and Death Receptor 4. |
| Q35747708 | Low Dose Total Body Irradiation Combined With Recombinant CD19-Ligand × Soluble TRAIL Fusion Protein is Highly Effective Against Radiation-Resistant B-Precursor Acute Lymphoblastic Leukemia in Mice |
| Q38191877 | Mass cytometry to decipher the mechanism of nongenetic drug resistance in cancer. |
| Q34464915 | Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression |
| Q48158195 | Mitochondrial levels determine variability in cell death by modulating apoptotic gene expression. |
| Q34393708 | Modeling dynamics of cell-to-cell variability in TRAIL-induced apoptosis explains fractional killing and predicts reversible resistance |
| Q38217477 | Molecular mechanisms and anti-cancer aspects of the medicinal phytochemicals rocaglamides (=flavaglines). |
| Q55156410 | N-glycosylation of mouse TRAIL-R restrains TRAIL-induced apoptosis. |
| Q50070105 | Nanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy |
| Q47740361 | Natural Agents-Mediated Targeting of Histone Deacetylases. |
| Q26772347 | Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy |
| Q37694101 | Non-canonical NFκB mutations reinforce pro-survival TNF response in multiple myeloma through an autoregulatory RelB:p50 NFκB pathway. |
| Q38913421 | Novel TRAIL sensitizer Taraxacum officinale F.H. Wigg enhances TRAIL-induced apoptosis in Huh7 cells |
| Q26768160 | Onto better TRAILs for cancer treatment |
| Q33731141 | PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy |
| Q38808957 | PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer. |
| Q36292383 | Piperlongumine and immune cytokine TRAIL synergize to promote tumor death |
| Q49379217 | Plasma-stimulated medium kills TRAIL-resistant human malignant cells by promoting caspase-independent cell death via membrane potential and calcium dynamics modulation |
| Q33695003 | Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells |
| Q37719266 | Polymeric mechanical amplifiers of immune cytokine-mediated apoptosis |
| Q50943002 | Polymeric nanoparticle-based delivery of TRAIL DNA for cancer-specific killing. |
| Q26771601 | Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand? |
| Q37641600 | Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide |
| Q51123259 | RGD and NGR modified TRAIL protein exhibited potent anti-metastasis effects on TRAIL-insensitive cancer cells in vitro and in vivo. |
| Q35183874 | Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia |
| Q55340117 | Relationship between the agonist activity of synthetic ligands of TRAIL-R2 and their cell surface binding modes. |
| Q39305649 | Restoring TRAIL Induced Apoptosis Using Naturopathy. Hercules Joins Hand with Nature to Triumph Over Lernaean Hydra. |
| Q38965072 | Selective TRAIL-induced cytotoxicity to lung cancer cells mediated by miRNA response elements |
| Q59799448 | Sensitization of renal carcinoma cells to TRAIL-induced apoptosis by rocaglamide and analogs |
| Q42709967 | Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy |
| Q53079276 | Silibinin sensitizes TRAIL-mediated apoptosis by upregulating DR5 through ROS-induced endoplasmic reticulum stress-Ca2+-CaMKII-Sp1 pathway. |
| Q29041079 | Small-molecule drug drives cancer cells to suicide |
| Q33576187 | Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells |
| Q59807366 | Sulforaphane from Cruciferous Vegetables: Recent Advances to Improve Glioblastoma Treatment |
| Q41778655 | Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels. |
| Q58700213 | Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma |
| Q37433463 | TRAIL on trial: preclinical advances in cancer therapy |
| Q39434911 | TRAIL, Wnt, Sonic Hedgehog, TGFβ, and miRNA Signalings Are Potential Targets for Oral Cancer Therapy |
| Q92757990 | TRAILblazing Strategies for Cancer Treatment |
| Q55012569 | Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells. |
| Q39072507 | The DeISGylase USP18 limits TRAIL-induced apoptosis through the regulation of TRAIL levels: Cellular levels of TRAIL influences responsiveness to TRAIL-induced apoptosis. |
| Q92662669 | The Mitochondrial Ca2+ Overload via Voltage-Gated Ca2+ Entry Contributes to an Anti-Melanoma Effect of Diallyl Trisulfide |
| Q37226262 | The herbal compound cryptotanshinone restores sensitivity in cancer cells that are resistant to the tumor necrosis factor-related apoptosis-inducing ligand |
| Q47832405 | The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement |
| Q38704582 | The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand |
| Q38990912 | The mitochondrial protein NLRX1 controls the balance between extrinsic and intrinsic apoptosis. |
| Q43468001 | The plant alkaloid and anti-leukemia drug homoharringtonine sensitizes resistant human colorectal carcinoma cells to TRAIL-induced apoptosis via multiple mechanisms. |
| Q61444104 | The relationship between autophagy and the immune system and its applications for tumor immunotherapy |
| Q90028589 | The role of long non-coding RNAs in mediating chemoresistance by modulating autophagy in cancer |
| Q38797635 | Trichostatin A potentiates TRAIL-induced antitumor effects via inhibition of ERK/FOXM1 pathway in gastric cancer |
| Q41762619 | Two-stage nanoparticle delivery of piperlongumine and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) anti-cancer therapy |
| Q92408464 | Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics |
| Q38861356 | Using natural products to promote caspase-8-dependent cancer cell death |
| Q92511522 | Weighted Fused Pathway Graphical Lasso for Joint Estimation of Multiple Gene Networks |
| Q36347307 | Withanolide E sensitizes renal carcinoma cells to TRAIL-induced apoptosis by increasing cFLIP degradation |
| Q41440890 | miR-133a Promotes TRAIL Resistance in Glioblastoma via Suppressing Death Receptor 5 and Activating NF-κB Signaling. |
| Q38638204 | microRNAs: An Emerging Paradigm in Lung Cancer Chemoresistance |
| Q90225121 | p53-Mediated Oxidative Stress Enhances Indirubin-3'-Monoxime-Induced Apoptosis in HCT116 Colon Cancer Cells by Upregulating Death Receptor 5 and TNF-Related Apoptosis-Inducing Ligand Expression |
| Q24299363 | Role of activating transcription factor 3 (ATF3) in endoplasmic reticulum (ER) stress-induced sensitization of p53-deficient human colon cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through |
Search more.